Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.